Join Our Newsletter - Get important industry news and analysis sent to your inbox – sign up to our e-Newsletter here
X

Kidney Disease (Nephropathy) accounts for 51.0% share of global Genito Urinary System And Sex Hormones clinical trial activity in 2020

25 Mar 2021 (Last Updated March 25th, 2021 14:58)

Kidney Disease (Nephropathy) accounted for a 51.0% share of the global clinical trials within the Genito Urinary System And Sex Hormones therapy area in 2020, registering a decrease of 7.2% when compared with the last ten-year average of 58.2% share, according to GlobalData.

  • Embed this chart
    Embed this chart into your website Copy and paste the code below into your website to display the chart.

Non-industry sponsored trials outnumber industry sponsored trials for Kidney Disease

Industry sponsored trials held a 34.7% share of all the clinical trials for Kidney Disease indication in 2020, registering an increase of 4.7% when compared with the ten-year average of 30.0%. Non-industry sponsored trials accounted for a 65.3% share in 2020, marking a decrease of 4.7% over the ten-year average of 70.0%.


  • Embed this chart
    Embed this chart into your website Copy and paste the code below into your website to display the chart.

Top regions of industry sponsored Kidney Disease trials

Asia-Pacific was the top region for industry sponsored Kidney Disease trials, accounting for a 51.6% share in 2020, when compared with the five-year average of 44.1% and ten-year average of 38.9%.

North America was at the second position with a 41.8% share in 2020, over the five-year average of 46.9% and ten-year average of 48.2%, followed by Europe with a 30.8% share in 2020, as against five-year and ten-year averages of 37.1% and 37.9% respectively.

Middle East and Africa stood fourth with a 4.4% share in 2020, compared with the five-year average of 6.9% and ten-year average of 7.7%, followed by South and Central America with a 4.4% share in 2020, over five-year and ten-year averages of 6.5% and 6.0% respectively.

  • Embed this chart
    Embed this chart into your website Copy and paste the code below into your website to display the chart.

The US was the top country for industry sponsored Kidney Disease trials, accounting for a 40.7% share in 2020, as against the five-year average of 46.1% and ten-year average of 46.8%.

China held a 24.2% share in 2020, over the five-year average of 13.5% and ten-year average of 8.3%, followed by Germany with a 12.1% share in 2020, compared with the five-year and ten-year averages of 16.9% and 18.1% respectively.

Australia held a 9.9% share in 2020, as against the five-year average of 10.2% and ten-year average of 8.6%.

Spain held a 9.9% share in 2020, over the five-year and ten-year averages of 10.9% and 10.7% respectively.

Top regions of non-industry sponsored Kidney Disease trials

Asia-Pacific was the top region for non-industry sponsored Kidney Disease trials, accounting for a 44.4% share in 2020 when compared with the five-year average of 45.5% and ten-year average of 45.1%.

Europe was at the second position with a 27.2% share in 2020, over the five-year and ten-year averages of 16.5% and 20.3% respectively, followed by North America with a 13.9% share in 2020, as against the five-year average of 18.7% and ten-year average of 19.2%.

Middle East and Africa stood at the fourth position with a 13.3% share in 2020, compared with the five-year average of 17.9% and ten-year average of 14.5%, followed by South and Central America with a 2.8% share in 2020, over the five-year and ten-year averages of 2.7% and 2.4% respectively.

  • Embed this chart
    Embed this chart into your website Copy and paste the code below into your website to display the chart.

China was the top country for non-industry sponsored Kidney Disease trials, accounting for a 22.8% share in 2020, as against the five-year average of 19.0% and ten-year average of 14.9%.

The US held a 12.2% share in 2020, over the five-year average of 15.0% and ten-year average of 15.5%, followed by Iran with a 10.6% share, compared with the five-year and ten-year averages of 14.1% and 11.6% respectively.

India held a 10.6% share in 2020, as against the five-year average of 7.9% and ten-year average of 5.5%.

Denmark held a 4.4% share in 2020, over the five-year average of 2.0% and ten-year average of 2.3%.

Phase I trials lead industry sponsored clinical trials for Kidney Disease in 2020

Phase I trials held a 47.1% share of industry sponsored clinical trials for Kidney Disease in 2020, over the five-year average of 43.6% and ten-year average of 37.8%.

Phase II trials held a 31.7% share in 2020, as against the five-year average of 28.3% and ten-year average of 29.0%. Phase III trials held a 16.3% share in 2020, compared with the five-year and ten-year averages of 18.3% and 20.8% respectively.

Phase IV trials held a 4.8% share in 2020, over the five-year average of 9.7% and ten-year average of 12.4%.

Phase II trials lead non-industry sponsored clinical trials for Kidney Disease in 2020

Phase II trials held a 38.8% share of non-industry sponsored clinical trials for Kidney Disease in 2020, over the five-year average of 46.5% and ten-year average of 47.0%.

Phase IV trials held a 31.6% share in 2020, as against the five-year average of 27.7% and ten-year average of 29.1%. Phase III trials held a 19.4% share, compared with the five-year and ten-year averages of 18.2% and 16.9% respectively.

Phase I trials held a 10.2% share in 2020, over the five-year average of 7.7% and ten-year average of 7.0%.

Methodology:
The clinical trials data used for the analyses were extracted from the Clinical Trials Database of GlobalData’s Pharma Intelligence Center. Clinical Trials are sourced from numerous government, non-government and company clinical trial registries worldwide alongside clinical research publications, scientific conferences, company websites, SEC filings and more. The information is gathered by a combination of automation and secondary research to ensure accuracy and validity. A small number of Phase 0, Phase I/II, Phase II/III, and Phase III/IV trials were combined with Phase I, Phase II, Phase III, and Phase IV trials, respectively.